DGAP-News: NEOVACS CONFIRMS ITS DEVELOPMENT STRATEGY IN THE

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
DGAP-News: NEOVACS CONFIRMS ITS DEVELOPMENT STRATEGY IN THE USA BY PARTICIPATING AT THE AMERICAN CONGRESS OF RHEUMATOLOGY IN BOSTON FROM 15TH TO 19TH OF NOVEMBER

DGAP-News: Neovacs S.A. / Key word(s): Conference NEOVACS CONFIRMS ITS DEVELOPMENT STRATEGY IN THE USA BY PARTICIPATING AT THE AMERICAN CONGRESS OF RHEUMATOLOGY IN BOSTON FROM 15TH TO 19TH OF NOVEMBER 12.11.2014 / 08:00 --------------------------------------------------------------------- NEOVACS CONFIRMS ITS DEVELOPMENT STRATEGY IN THE USA BY PARTICIPATING AT THE AMERICAN CONGRESS OF RHEUMATOLOGY IN BOSTON FROM 15TH TO 19TH OF NOVEMBER Paris, 12 November 2014 - NEOVACS (Alternext Paris : ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, will participate at the American Congress of Rheumatology in Boston from 15th to 19th of November, strongly confirming its desire to develop itself in the USA. On the occasion of the worldwide largest Congress of Rheumatology which starts at the end of this week in Boston, Neovacs will be attending with a large booth. It will present and explain the company's technology of therapeutic vaccines inducing the production of polyclonal antibodies. Pictures of the booth and explanation panels will be online next Monday, 17th of November. The Clinical Advisory Board for the study in Lupus will meet at that occasion in order to finalize the protocol of the planned multicentric Phase IIb study. The objective of this study will be to demonstrate the clinical efficacy of the Kinoid IFNα in Lupus (SLE). Lupus is a serious autoimmune disease, very invalidating and potentially fatal, which affects more than 5 million people in the world, particularly women. Currently, there is no satisfying therapy available against this disease. The clinical trial will be initiated mid of 2015 in Asia, Europe and America. During this Congress, Neovacs will also present the results of a study realized with an academic partner, the University Clinic Saint Luc in Brussels, poster 2019, which demonstrates the differential implication of type 1 Interferon in the clinical expressions of Lupus disease and the major importance of IFNα in this pathology, particularly in renal affections. Finally, Neovacs will make available to the attendants of this Congress, the results presented as a poster during EULAR 2014 in Paris last June. This study demonstrated the clear superiority of the polyclonal antibodies induced by the administration of IFNα-Kinoid for the neutralization of IFNα, in comparison with monoclonal antibodies. About Neovacs Neovacs is a biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by six patent families that run until at least 2023) Neovacs is focusing its development efforts on two active immunotherapies: TNF-Kinoid is being developed for the treatment of TNF-mediated autoimmune diseases such as rheumatoid arthritis and Crohn's disease, whereas IFNα-Kinoid is being developed for the indication of lupus. Neovacs is also conducting preclinical works on IFNα-Kinoid in certain chronic viral infections, VEGF-Kinoid in Age-related Macular Degeneration (AMD) and solid tumors, and IL-4-Kinoid for the treatment of allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. For more information on Neovacs, visit www.neovacs.fr Press & Financial Communication France - Publicis Stéphanie Tabouis +33 (0) 1 44 82 46 35 stéphanie.tabouis@consultants.publicis.fr Aubane de Gélis +33 (0) 1 44 82 46 38 aubane.de-gelis@consultants.publicis.fr --------------------------------------------------------------------- 12.11.2014 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: Neovacs S.A. 3-5, Impasse Reille 75014 Paris France Phone: +33 (0)1 53 10 93 00 Fax: +33 (0)1 53 10 93 03 E-mail: www.neovacs.fr Internet: info@neovacs.fr ISIN: FR0004032746 WKN: A1CVKR Listed: Freiverkehr in Stuttgart; Frankfurt in Open Market End of News DGAP News-Service --------------------------------------------------------------------- 296572 12.11.2014

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Vuzix Bets on Lightweight Color Glasses for OEM Partners

Updated Category News Views 144

Forty grams is where this story gets interesting, because faces are ruthless product testers. People will tolerate plenty of clever technology right up until it pinches, looks goofy, leaks light, or makes them feel like they are wearing a science project. Vuzix is trying to clear that hurdle with Ultralite Color, a full-color AI eyewear reference platform built for OEM...

Continue Reading
Lotte's Songdo Plant 1 Puts 120,000 Liters on Deck

Updated Category News Views 95

A 120,000-liter biomanufacturing plant is not a ribbon-cutting trinket; it is a serious industrial bet that has to earn its keep one qualified batch at a time. LOTTE Biologics has completed Plant 1 at its Songdo Bio Campus in Incheon, South Korea, giving the company a sizable new production base as it tries to become a more consequential player in the global CDMO...

Continue Reading
Chaos Zero Nightmare's Award Is a Useful Signal for Games

Updated Category News Views 239

A story award can be easy to sneer at until a live-service game earns one across three markets. Smilegate's Chaos Zero Nightmare, a dark fantasy roguelike RPG developed by Super Creative, was named Best Story in Google Play's Best of 2026 awards for Taiwan, Hong Kong and Macau. That is not a sales figure, not a profit disclosure, and certainly not proof that a hit has...

Continue Reading
Parents Hand Kids Devices Years Before They Intended

Updated Category News Views 286

A nine-year-old with a smartphone used to raise eyebrows; this survey says it is increasingly the household baseline. All About Cookies, working with parental-control company Bark, surveyed U.S. parents and found that children typically receive personal devices well before their parents believe they should. That mismatch is not some cute little parenting contradiction. It...

Continue Reading
BetterInvesting Puts ELMD and FIVE Under a Fresh Lens

Updated Category News Views 74

Two familiar market traps are hiding in this otherwise useful announcement: mistaking a study candidate for a buy signal, and treating the word undervalued like it fell from a mountaintop. BetterInvesting has named Electromed Inc. as its “Stock to Study” and Five Below Inc. as its “Undervalued Stock” for the January-February 2027 issue of its magazine. That is...

Continue Reading
Kids First Data Sharing Raises Pediatric Research Bar

Updated Category News Views 73

Thirty-eight thousand children’s records are not a headline gimmick; they are a serious argument for treating research data as an asset that must keep working after the first study ends. The Gabriella Miller Kids First Data Resource Center’s ten-year review, published in the September 2026 issue of The American Journal of Human Genetics, makes that argument with...

Continue Reading
Leqembi’s Real-World Data Gives BioArctic More Weight

Updated Category News Views 121

A Harder Look at Treatment Staying Power Alzheimer’s drug data rarely arrive without a thicket of caveats, and that is exactly why this Leqembi update deserves a calm read rather than a victory lap. BioArctic’s partner Eisai presented a three-year real-world analysis at CTAD 2026 covering 560 early Alzheimer’s patients across 13 U.S. sites. The headline is striking:...

Continue Reading
MetaComp Targets ASEAN's Cross-Border Payment Snarl

Updated Category News Views 90

ASEAN payment plumbing is still a patchwork, and MetaComp is betting that patchwork has finally become painful enough to fix. The Singapore-based payments firm says its StableX Agentic Network has topped 1,000 members and reaches more than 100,000 users in its first year. That is a respectable early footprint, not a victory lap. Cross-border payments are littered with...

Continue Reading
Lake Ridge Sets $0.68 Dividend as 2026 Payouts Rise

Updated Category News Views 96

A community bank raising its cash return is not fireworks, but it gets my attention faster than another glossy growth slogan. Lake Ridge Bancorp has declared a fourth-quarter 2026 dividend of $0.68 per share, payable December 16 to shareholders of record on November 30. That is a plain, useful announcement from OTCQX:LRBI, and plain is often underrated when you are...

Continue Reading
FP Markets Puts Anthropic CFD Into the AI Trading Mix

Updated Category News Views 28

A fresh AI bellwether is about to meet the CFD crowd. FP Markets says it will add an Anthropic share CFD, identified as ANT.xnas, to its lineup on November 19, 2026. Clients worldwide are slated to access it through MetaTrader 5, cTrader, and TradingView. That is a tidy distribution expansion, but it lands with the usual AI-market fireworks already hissing in the...

Continue Reading

Top 5 Most Recently Viewed Articles

Trifork Group Launches 2025 Share-Based Incentive Program

Updated Category News Views 333

Trifork's Innovative Share-Based Incentive Program The Trifork Group AG has taken a significant step towards enhancing employee satisfaction and retention with the introduction of its Share-Based Incentive Program for 2025. This strategic decision supports Trifork’s ongoing commitment to fostering a motivated workforce and aligns with the company’s vision for growth...

Continue Reading
China's Agricultural Modernization: Dezhou's Vital Role

Updated Category News Views 40

Modern Farming Revolution in Dezhou Fifteen years ago, farming technology in Dezhou was a distant dream; today, it's a shining reality. Picture this: Song Zhijie, a veteran farmer, reflecting on a dusty 1997 summer harvest. Now, he sits in air-conditioned cabins, operating state-of-the-art machinery, basking in the efficiency that modern technology has granted. Dezhou, a...

Continue Reading
Exploring the Growth of the Cultured Wheat Market: 2024-2034

Updated Category News Views 142

Exploring the Growth of the Cultured Wheat Market The cultured wheat market is set for remarkable growth, with projections indicating an increase from USD 704.1 million in 2024 to USD 1,273.0 million by 2034. This growth translates to a solid compound annual growth rate (CAGR) of 6.1% over the decade. The rising demand for cultured wheat is driven by several factors,...

Continue Reading
Transforming Urban Mobility: Hikvision's AIoT Innovations

Updated Category News Views 292

Hikvision showcased its game-changing AIoT innovations at the ITS World Congress, zeroing in on making urban mobility safer, smarter, and greener. Their booth was abuzz with tech that’s not just flashy; it’s a serious play aimed at reshaping how we think about transport. The emphasis here? A commitment to road safety that's palpable, with cutting-edge solutions that...

Continue Reading
Avem Health Partners Welcomes Military Veterans to Board of Directors

Updated Category News Views 90

Enhancing Leadership at Avem Health Partners Avem Health Partners, a well-respected hospital management company based in Oklahoma City, is excited to announce the recent appointments of Keith Walker and Barbara Holcomb to its Board of Directors. This strategic decision aims to infuse the organization with a wealth of experience from both military and corporate...

Continue Reading